collection
MENU ▼
Read by QxMD icon Read
search

LES

shared collection
106 papers 25 to 100 followers
https://www.readbyqxmd.com/read/29788808/epidemiology-of-cutaneous-lupus-erythematosus-and-the-associated-risk-of-systemic-lupus-erythematosus-a-nationwide-cohort-study-in-denmark
#1
M Prütz Petersen, S Möller, A Bygum, A Voss, M Bliddal
Objectives The objectives of this paper are to describe the epidemiology of cutaneous lupus erythematosus (CLE) and its subtypes in Denmark, and to investigate the probability of receiving a subsequent diagnosis of systemic lupus erythematosus (SLE) and the related time course. Methods A nationwide registry-based cohort study was conducted in Denmark based on data from the Danish National Patient Registry from 1998 to 2013 using International Classification of Diseases, Revision 10. Results We identified 2380 patients with CLE...
January 1, 2018: Lupus
https://www.readbyqxmd.com/read/29788809/using-hydroxychloroquine-and-protecting-the-retina
#2
K Schreiber, N Davies, B J Hunt
No abstract text is available yet for this article.
January 1, 2018: Lupus
https://www.readbyqxmd.com/read/29783918/rituximab-mediated-late-onset-neutropenia-in-systemic-lupus-erythematosus-distinct-roles-of-baff-and-april
#3
I Parodis, F Söder, F Faustini, Z Kasza, I Samuelsson, A Zickert, E Svenungsson, R F van Vollenhoven, V Malmström, F Wermeling, I Gunnarsson
Objective Rituximab-mediated late-onset neutropenia (LON) has been described in various diseases. We investigated its occurrence, consequences and contributing factors in patients with systemic lupus erythematosus (SLE). Methods Rituximab-treated patients from the Karolinska University Hospital ( n = 107) were surveyed. LON was defined as an absolute neutrophil count <1500 cells/μl, occurring four weeks to two years following rituximab treatment, or later during sustained B-cell depletion. Serum levels of B-cell-related cytokines and growth factors of the myeloid lineage were determined using enzyme-linked immunosorbent assay...
January 1, 2018: Lupus
https://www.readbyqxmd.com/read/29180126/belimumab-in-the-treatment-of-systemic-lupus-erythematous-an-evidence-based-review-of-its-place-in-therapy
#4
REVIEW
Frederico Marcondes, Morton Scheinberg
INTRODUCTION: Systemic lupus erythematous is an autoimmune disease with diverse clinical features and has its development associated with a complexity of genetic, hormonal and environmental factors and the development of autoantibodies. Identification of new treatments is currently an area of intense investigation. Belimumab is the first biologic approved for the treatment of the disease inhibiting the excessive B cell activity observed in these patients and consequently reduction of autoantibodies...
February 2018: Autoimmunity Reviews
https://www.readbyqxmd.com/read/29779437/procalcitonin-and-c-reactive-protein-as-markers-of-infection-in-systemic-lupus-erythematosus-the-controversy-continues
#5
E El-Serougy, H S Zayed, N M Ibrahim, L A Maged
Objective The objective of this paper is to investigate the utility of serum procalcitonin (PCT) and C-reactive protein (CRP) as markers of infection in systemic lupus erythematosus (SLE) patients. Patients and methods Sixty-nine SLE patients with symptoms and signs of infection proved by culture and/or a favorable response to antibiotics and 69 SLE patients without infection were included. Serum PCT and plasma high-sensitivity CRP were assessed by an enzyme-linked immunosorbent assay. Results SLE patients with infection had a significantly higher level of CRP than those without infection ((median (IQR) 104...
January 1, 2018: Lupus
https://www.readbyqxmd.com/read/29611488/lupus-nephritis-a-treatment-update
#6
Fahad Aziz, Kunal Chaudhary
BACKGROUND: Lupus nephritis (LN) is a common complication in many patients with systemic lupus erythematosus, although renal-limited lupus nephritis has been reported as well. Early diagnosis of lupus nephritis is critical as early detection and effective treatment can improve renal outcomes in such patients. OBJECTIVE: The treatment of lupus nephritis is largely determined based on the histological class present on the renal biopsy specimen. In most cases, Class I and II of lupus nephritis do not require any specific treatment, but class III and IV lupus nephritis require immunosuppressive therapy...
April 3, 2018: Current Clinical Pharmacology
https://www.readbyqxmd.com/read/29688145/use-of-echocardiography-at-diagnosis-and-detection-of-acute-cardiac-disease-in-youth-with-systemic-lupus-erythematosus
#7
J C Chang, A M Knight, R Xiao, L M Mercer-Rosa, P F Weiss
Objectives There are no guidelines on the use of echocardiography to detect cardiac manifestations of childhood-onset systemic lupus erythematosus (SLE). We quantify the prevalence of acute cardiac disease in youth with SLE, describe echocardiogram utilization at SLE diagnosis, and compare regional echocardiogram use with incident cardiac diagnoses. Methods Using the Clinformatics® DataMart (OptumInsight, Eden Prairie, MN) de-identified United States administrative database from 2000 to 2013, we identified youth ages 5-24 years with new-onset SLE (≥3 ICD-9 SLE codes 710...
July 2018: Lupus
https://www.readbyqxmd.com/read/29699441/simvastatin-reduces-antiphospholipid-antibodies-formation-in-patients-with-systemic-lupus-erythematosus-a-preliminary-study
#8
P J Kotyla
No abstract text is available yet for this article.
January 1, 2018: Lupus
https://www.readbyqxmd.com/read/29608745/clinical-image-bullous-lupus-erythematosus
#9
Mohammad Ali, Ashish Sharma, Arvind Ahuja, Vivek Arya
No abstract text is available yet for this article.
March 28, 2018: Rheumatology
https://www.readbyqxmd.com/read/29673280/safety-and-efficacy-of-thrombopoeitin-mimetics-for-refractory-immune-thrombocytopenia-purpura-in-patients-with-systemic-lupus-erythematosus-or-antiphospholipid-syndrome-a-case-series
#10
A Lusa, A Carlson
Background While thrombopoeitin (TPO) agonists that act to simulate platelet production have been approved for use in steroid-refractory chronic immune thrombocytopenia purpura (ITP), there are few data on the safety and efficacy of these medications in patients with concurrent systemic lupus erythematosus (SLE) or antiphospholipid syndrome (APS). Given that these agents can increase all hematopoietic cell lineages, it is unclear if there is an increased risk for exacerbation of the underlying lymphocyte-driven autoimmune disease in this population...
January 1, 2018: Lupus
https://www.readbyqxmd.com/read/29642752/lupus-myocarditis-a-single-center-experience-and-a-comparative-analysis-of-observational-cohort-studies
#11
J Tanwani, K Tselios, D D Gladman, J Su, M B Urowitz
Background Lupus myocarditis (LM) is reported in 3-9% of patients with systemic lupus erythematosus (SLE) but limited evidence exists regarding optimal treatment and prognosis. This study aims to describe LM in a defined lupus cohort as compared with the existing literature. Patients and methods Patients with LM were identified from the University of Toronto Lupus Clinic database. Diagnosis was based on clinical manifestations and electrocardiographic, imaging, and biochemical criteria. Demographic, clinical, diagnostic and therapeutic variables and outcomes were collected in a standardized data retrieval form...
July 2018: Lupus
https://www.readbyqxmd.com/read/29629608/intravenous-pulses-of-methylprednisolone-to-treat-flares-of-immune-mediated-diseases-how-much-how-long
#12
A Danza, I Borgia, J I Narváez, A Baccelli, C Amigo, M Rebella, V Domínguez
Introduction Glucocorticoids are widely used in the treatment of immune-mediated diseases. Despite their widespread use, details on dosing, effectiveness and adverse effects are yet to be determined. Objective To know the current use of methylprednisolone (MTP) in the management of immune-mediated conditions, evaluating the relationship among doses, therapeutic response and adverse effects. Methodology A multicenter retrospective cohort study was designed, including patients who received intravenous pulses of MTP between 1 January 2013 and 12 December 2015 in three different hospitals in Uruguay...
June 2018: Lupus
https://www.readbyqxmd.com/read/29559714/the-non-haemostatic-role-of-platelets-in-systemic-lupus-erythematosus
#13
REVIEW
Petrus Linge, Paul R Fortin, Christian Lood, Anders A Bengtsson, Eric Boilard
Dysregulation of lymphocyte function, accumulation of autoantibodies and defective clearance of circulating immune complexes and apoptotic cells are hallmarks of systemic lupus erythematosus (SLE). Moreover, it is now evident that an intricate interplay between the adaptive and innate immune systems contributes to the pathogenesis of SLE, ultimately resulting in chronic inflammation and organ damage. Platelets circulate in the blood and are chiefly recognized for their role in the prevention of bleeding and promotion of haemostasis; however, accumulating evidence points to a role for platelets in both adaptive and innate immunity...
March 21, 2018: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/29559718/type-i-interferon-in-rheumatic-diseases
#14
REVIEW
Theresa L Wampler Muskardin, Timothy B Niewold
The type I interferon pathway has been implicated in the pathogenesis of a number of rheumatic diseases, including systemic lupus erythematosus, Sjögren syndrome, myositis, systemic sclerosis, and rheumatoid arthritis. In normal immune responses, type I interferons have a critical role in the defence against viruses, yet in many rheumatic diseases, large subgroups of patients demonstrate persistent activation of the type I interferon pathway. Genetic variations in type I interferon-related genes are risk factors for some rheumatic diseases, and can explain some of the heterogeneity in type I interferon responses seen between patients within a given disease...
March 21, 2018: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/29546774/the-ratio-of-erythrocyte-sedimentation-rate-to-c-reactive-protein-is-useful-in-distinguishing-infection-from-flare-in-systemic-lupus-erythematosus-patients-presenting-with-fever
#15
E Littlejohn, W Marder, E Lewis, S Francis, J Jackish, W J McCune, E C Somers
Background Both C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) can be elevated in systemic lupus erythematosus (SLE) flare and infection, and are therefore of limited utility for distinguishing between the two conditions in febrile SLE patients. Methods A medical records review of hospitalizations (1997-2006) of SLE patients in the Michigan Lupus Cohort was performed. Eligible hospitalizations were those in which patients presented with a temperature of >100.3°F or with subjective fevers as a presenting complaint at admission...
June 2018: Lupus
https://www.readbyqxmd.com/read/29288864/assessment-of-subclinical-atherosclerosis-in-systemic-lupus-erythematosus-a-systematic-review-and-meta-analysis
#16
Pauline Henrot, Jennifer Foret, Thomas Barnetche, Estibaliz Lazaro, Pierre Duffau, Julien Seneschal, Thierry Schaeverbeke, Marie-Elise Truchetet, Christophe Richez
OBJECTIVES: To determine whether subclinical atherosclerosis is increased in patients with systemic lupus erythematosus (SLE) compared to healthy individuals, using carotid intima-media thickness (CIMT), carotid plaque (CP) presence or flow-mediated dilatation (FMD). METHODS: A systematic literature search was performed using MedLine, Embase and Cochrane databases. Two reviewers independently screened the articles to identify studies that compared the rates of atherosclerosis in SLE patients versus healthy controls...
March 2018: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/29481673/macrophage-activation-syndrome-in-adults-recent-advances-in-pathophysiology-diagnosis-and-treatment
#17
Stuart J Carter, Rachel S Tattersall, Athimalaipet V Ramanan
Haemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome, which if not promptly treated, can lead rapidly to critical illness and death. HLH is termed macrophage activation syndrome (MAS) when associated with rheumatic disease (where it is best characterized in systemic JIA) and secondary HLH (sHLH) when associated with other triggers including malignancy and infection. MAS/sHLH is rare and coupled with its mimicry of other conditions, is underrecognized. These inherent challenges can lead to diagnostic and management challenges in multiple medical specialties including haematology, infectious diseases, critical care and rheumatology...
February 21, 2018: Rheumatology
https://www.readbyqxmd.com/read/29440000/assay-variation-in-the-detection-of-antinuclear-antibodies-in-the-sera-of-patients-with-established-sle
#18
David S Pisetsky, Diane M Spencer, Peter E Lipsky, Brad H Rovin
OBJECTIVE: The expression of antinuclear antibodies (ANA) is considered almost constant in systemic lupus erythematosus (SLE), although recent experience has suggested that many subjects with SLE considered for clinical trials are ANA negative at screening. The objective of this study is to determine whether assay variation can influence ANA detection in patients with established SLE. METHODS: Sera from 103 patients with established SLE were tested using three different immunofluorescence assays (IFA) for ANA determination...
June 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29451069/arthritis-and-use-of-hydroxychloroquine-associated-with-a-decreased-risk-of-macrophage-activation-syndrome-among-adult-patients-hospitalized-with-systemic-lupus-erythematosus
#19
E M Cohen, K D'Silva, D Kreps, M B Son, K H Costenbader
Background Macrophage activation syndrome (MAS) is an uncommon but serious complication of systemic lupus erythematosus (SLE). We aimed to identify factors associated with MAS among adult hospitalized SLE patients. Methods Within the Brigham and Women's Hospital (BWH) Lupus Center Registry, we identified adult SLE patients > age 17 who had been hospitalized from 1970 to 2016, with either ferritin > 5000 ng/ml during admission or "macrophage activation syndrome" or "MAS" in discharge summary...
June 2018: Lupus
https://www.readbyqxmd.com/read/29371202/complement-activation-predicts-adverse-pregnancy-outcome-in-patients-with-systemic-lupus-erythematosus-and-or-antiphospholipid-antibodies
#20
Mimi Y Kim, Marta M Guerra, Elianna Kaplowitz, Carl A Laskin, Michelle Petri, D Ware Branch, Michael D Lockshin, Lisa R Sammaritano, Joan T Merrill, T Flint Porter, Allen Sawitzke, Anne M Lynch, Jill P Buyon, Jane E Salmon
OBJECTIVE: Studies in mouse models implicate complement activation as a causative factor in adverse pregnancy outcomes (APOs). We investigated whether activation of complement early in pregnancy predicts APOs in women with systemic lupus erythematosus (SLE) and/or antiphospholipid (aPL) antibodies. METHODS: The PROMISSE Study enrolled pregnant women with SLE and/or aPL antibodies (n=487) and pregnant healthy controls (n=204) at <12 weeks gestation and evaluated them monthly...
April 2018: Annals of the Rheumatic Diseases
label_collection
label_collection
6416
1
2
2018-02-16 23:31:23
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"